ad image

FDA Review

1 / 1
AstraZeneca
FDA Priority Review

[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer

AstraZeneca

PR-M10-19-NI-025Oct 17, 2019
Daiichi-Sankyo
FDA Review

Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Daiichi-Sankyo

PR-M06-19-NI-045Jun 26, 2019
1 / 1